Suven Life Sciences, a biopharmaceutical company, has undergone USFDA renewal inspection at their facility in Pashamylaram, near Hyderabad for the manufacture and supply of active pharmaceutical ingredients (bulk drugs), intermediates and formulations under cGMP

Based on the inspection and the review thereafter USFDA has classified Suven facility at Pashamylaram as acceptable for manufacture and supply of active pharmaceutical ingredients, intermediates and formulations.

So far Suven Life Sciences has filed 29 DMF's and 1 ANDA from this facility which is FDA complaint under cGMP and continued after renewal inspection.

Shares of the company gained Rs 4.2, or 5.64%, to trade at Rs 78.65. The total volume of shares traded was 284,399 at the BSE (9.55 a.m., Wednesday).